RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New 'In Vivo' CAR-T therapy tested for Tough-to-Treat blood cancer
Disease control Not yet recruitingThis is a very early study to check the safety and first signs of effectiveness of a new type of CAR-T therapy called IASO206 for patients with multiple myeloma that has come back or stopped responding to standard treatments. The therapy is designed to be given directly into the …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 02, 2026 02:26 UTC
-
First-in-Human trial launches for aggressive blood cancer combo
Disease control Not yet recruitingThis is the first study to test a new drug, REGN17372, in combination with an existing drug, linvoseltamab, in people with advanced multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find a safe dose for the combination and see if…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 02, 2026 02:26 UTC
-
New 'Living Drug' trial offers hope for Tough-to-Treat blood cancer
Disease control Not yet recruitingThis early-stage study is testing a new type of treatment called IASO104, a CAR-T cell therapy, for people with multiple myeloma that has come back or stopped responding to other treatments. Doctors will give patients their own modified immune cells to try to fight the cancer. Th…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 02, 2026 02:26 UTC
-
Double-Punch attack on Tough-to-Treat blood cancer
Disease control Not yet recruitingThis early-stage study is testing a new two-step approach for patients with multiple myeloma that has come back or stopped responding to many standard treatments. First, patients receive a special antibody drug (BCMA/CD3 bispecific antibody) to help prepare their body. Then, they…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Double-Punch therapy tested for Tough-to-Treat blood cancer
Disease control Not yet recruitingThis early-phase study is testing a new two-step approach for patients with multiple myeloma that has come back or stopped responding to many standard drugs. First, patients receive an antibody drug (QLS32015) that helps the immune system target cancer cells. This is followed by …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Radiation 'Priming' tested to supercharge cancer drug
Disease control Not yet recruitingThis study is testing whether giving low doses of radiation therapy before a new drug called elranatamab can help the drug work better against a hard-to-treat form of multiple myeloma. It will involve about 34 adults whose cancer has returned or stopped responding to standard tre…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 12, 2026 13:50 UTC